The rejection of an organ after a transplant is a very frequent problem and that represents a serious question for the patient if it is not detected in time. The current gold standard for the diagnosis of rejection is a biopsy. However, biopsies are undetermined in up to 30 percent of cases.

There is increasing interest in the use of non-invasive biomarkers to reduce the risks posed by invasive biopsy for monitoring solid organ transplants (SOTs). One of these promising markers is the presence of donor-derived cell-free DNA (dd-cfDNA) in the urine or blood of transplant recipients.

By detecting dd-cfDNA in a patient, we can distinguish early antibody-mediated rejection from non-antibody-mediated rejection. This type of analysis works to study the possible rejection of different organs in the recipient patient (heart, kidney, liver, among others). This in order to grant specific treatments in the early stages to the patient so that the rejection is controlled or prevented.

Cancer is the name given to a group of related diseases where some of the body's cells begin to divide without stopping and spread in the surrounding tissues. Some types of cancer are frequently associated with specific genetic mutations.

Currently, the traditional invasive detection method requires surgical intervention, which can be bothersome for the patient, requiring (sometimes) long recovery times, therefore, the use of new, less invasive and effective techniques is important.

We use the circulating tumor DNA (ctDNA) screening technique for the detection of biomarkers that allow us to more accurately and promptly detect suspected cancer development in some patients, as well as to generate treatments more specific, known as targeted therapy.

Using DNA tests, it is possible to identify missing persons by comparing the genetic profile of remains found with a genetically close relative. This service seeks to bring peace and hope to the families of the victims.

Carrying out this study of biological inheritance seeks to provide objective and useful information to legal problems through the analysis and comparison of the variability present in DNA.

Genetic diseases often occur due to mutations that can be inherited or can develop in response to negative environmental factors such as viruses or toxins. Some of the most common genetic diseases are disorders such as neuropathies, cystic fibrosis, diabetes, hypothyroidism, Down syndrome, autism, hereditary cardiomyopathies, among others.

On some occasions, it is difficult to determine the origin of a disease using traditional diagnoses, so genetic tests can be used to confirm a diagnosis in an individual presenting certain symptoms or to monitor the prognosis of a disease or the response to a medical treatment.

The non-invasive prenatal test (NIPT) seeks to assess the risk of the fetus being born with certain genetic abnormalities through sequencing and new generation technologies, using a blood sample from the mother. In which we mainly look for aneuploidies of a chromosome caused by the presence of an extra or missing copy of a chromosome.

We have an accuracy of 99.2% in detecting the risk of fetal trisomies. There are other diagnostic tests, but they are considered invasive procedures for pregnancy and carry an implicit risk of abortion.

COVID-19 is a pathogenic virus that affects humans, a member of the betacoronavirus group, capable of spreading through particles of saliva and fomites, its symptoms are related to severe acute respiratory syndrome (SARS) and is similar to other diseases such as Influenza or the seasonal flu. This coronavirus has a high infection capacity and generates respiratory complications that if not treated in time can lead to the death or be left with sequelae.

The paternity test determines and compares the footprint or map of the alleged father and the child to know the biological filiation, which is carried out from the DNA obtained. The results have a reliability of 100% if the result is negative and 99.99% if it is positive.

Customized sequencing services of different organisms using next-generation technologies. Sequencing of specific genes, as well as entire genomes (such as bacteria, fungi, viruses, and some other organisms). We also offer de novo sequencing services, allowing fast and accurate characterization of species without a reference genome.

With our technology, we are able to perform RNA sequencing services, which can allow the performance of different studies such as transcriptomics. Our staff is trained to offer you advice and answer your questions depending on what you want to sequence, so that you obtain the best results in your study.